8 September 2021,
Cipla has written to the National Pharmaceutical Pricing Authority to allow a price hike of asthma and certain other respiratory drugs.
It said the production cost of certain drugs has increased as the price of a critical ingredient, propellant P227, rose by 300%. Cipla said the products impacted are a “small subset” of the overall basket of its respiratory products.
-NAV GILL
